Additive effect of targeted lung denervation plus drug in patients with COPD

Coenraad Frederik Nicolaas Koegelenberg (Cape Town, South Africa), Coenraad Koegelenberg, Johan Theron, Dirk-Jan Slebos, Karin Klooster, Martin Mayse, Chris T. Bolliger

Source: International Congress 2015 – Novel treatments for cough, asthma, COPD and bronchiectasis
Session: Novel treatments for cough, asthma, COPD and bronchiectasis
Session type: Thematic Poster Session
Number: 3963
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Coenraad Frederik Nicolaas Koegelenberg (Cape Town, South Africa), Coenraad Koegelenberg, Johan Theron, Dirk-Jan Slebos, Karin Klooster, Martin Mayse, Chris T. Bolliger. Additive effect of targeted lung denervation plus drug in patients with COPD. Eur Respir J 2015; 46: Suppl. 59, 3963

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Long-term safety of bilateral targeted lung denervation in patients with COPD in a single procedure
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015


Comparison of protective effect of bronchodilators in COPD
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015

Two-year safety of targeted lung denervation in patients with moderate to severe COPD
Source: International Congress 2015 – Bronchoscopic treatment of COPD and asthma: valves, coils, thermoplastics and something more
Year: 2015

Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014

The effect of statin therapy in patients with chronic obstructive airway disease
Source: International Congress 2015 – COPD: notable points
Year: 2015


The adherence to inhaled drugs in COPD patients: Effect on survival
Source: International Congress 2015 – Treatment and control of respiratory disease
Year: 2015

The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014


Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Lung function, symptoms and prescription of inhaled steroids and long acting β2 agonists in patients managed by an integrated COPD team
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016


Effect of breathing parameters on lung dose in case of two combination drugs used in asthma and COPD therapy
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016


Effect of dual bronchodilation with indacaterol/glycopirronium on small airways resistance in patients with stable COPD
Source: International Congress 2016 – Non-inflammatory COPD monitoring
Year: 2016


GLISTEN Study subanalysis: Glycopyrronium differentially improves lung function, health status and rescue medication use when added to salmeterol/fluticasone in COPD severity groups
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015

Once-daily QVA149 improves dyspnoea, lung function and reduces rescue medication use in symptomatic patients with COPD using LAMA as prior medication: The BLAZE study
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014


Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy
Source: International Congress 2015 – Advances in the future treatment of COPD
Year: 2015

Effect of exacerbation history and ICS use on outcomes in COPD patients from the TIOSPIR™ trial
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015


The effect on mortality of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A focus on the frequent exacerbator phenotype
Source: International Congress 2015 – COPD and lung function: risk factors and outcomes
Year: 2015

LATE-BREAKING ABSTRACT: The novel inhaled dual PDE3/4 inhibitor RPL554 produces significant additional improvements in lung function when administered on top of existing standard of care in COPD patients
Source: International Congress 2016 – Late-breaking topics in airways disease
Year: 2016


Estimation of tiotropium efficacy at the COPD patients with group D
Source: International Congress 2015 – Different data in COPD
Year: 2015


The influence of type of inhalation device on adherence of COPD patients to inhaled medication
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013


Dual bronchodilation with once-daily QVA149 improves lung function and reduces exacerbations in patients with COPD: The IGNITE trials
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013